Amprologix to attend London’s Investival Showcase
23 October 2024Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in…
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in London on 18th November 2024. We look forward to meeting industry partners and investors who share our passion for developing new treatments to combat the rising global threat from antimicrobial resistance, including superbugs like MRSA and VRE. For […]
Amprologix files the first of a new series of patents protecting novel molecular structures for the treatment of bacterial infections. July 2024 Amprologix has filed its first patent in a series aimed at developing novel molecular structures for the treatment of bacterial infections. This significant milestone stems from discoveries made by Amprologix's proprietary AI “discovery […]
Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is delighted to receive confirmation of its success in securing a £1M Biomedical Catalyst award from Innovate UK for its Tobraderm project. The project will advance the company’s NI01 lead compound through late-preclinical testing for common […]